<DOC>
	<DOCNO>NCT00086944</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose oblimersen give together rituximab combination chemotherapy see well work treat patient relapsed refractory aggressive non-Hodgkin 's lymphoma . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy , ifosfamide , carboplatin , etoposide , work different way stop cancer cell divide stop grow die . Oblimersen may increase effectiveness chemotherapy make cancer cell sensitive drug</brief_summary>
	<brief_title>Oblimersen , Rituximab Combination Chemotherapy Treating Patients With Relapsed Refractory Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose oblimersen give combination rituximab , ifosfamide , carboplatin , etoposide patient relapse refractory aggressive B-cell non-Hodgkin 's lymphoma . II . Determine safety toxicity regimen patient . III . Determine complete partial response rate patient treat regimen . SECONDARY OBJECTIVES : I . Determine duration response , overall survival , time progression patient treat regimen . II . Determine effect regimen hematopoietic stem cell kinetics yield patient . OUTLINE : This multicenter , phase I , dose-escalation study oblimersen follow phase II study . Phase I : Patients receive GRICE comprise oblimersen IV continuously day 1-5 , rituximab IV , ifosfamide IV continuously 24 hour , carboplatin IV 1 hour day 4 , etoposide IV 30 minute daily day 4-6 . Treatment repeat every 14 day 3 course . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 7 continue blood count recover OR one dose pegfilgrastim SC day 7 course 1 2 . For course 3 , patient receive G-CSF SC twice daily begin day 7 continue stem cell collection complete . Patients respond disease eligible autologous SCT may receive 8 total course GRICE 2 additional course beyond maximal response . Patients respond disease GRICE eligible autologous SCT remove study undergo autologous SCT study . Cohorts 3-6 patient receive escalate dos oblimersen maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Phase II : Patients receive oblimersen MTD determine phase I rituximab , ifosfamide , carboplatin , etoposide follow G-CSF pegfilgrastim phase I . In phase , treatment continue absence disease progression , unacceptable toxicity , patient becomes candidate autologous SCT . Patients follow survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically confirm aggressive Bcell nonHodgkin 's lymphoma Any 1 one follow histological subtypes phase I : Grade 3 follicular center lymphoma Diffuse large Bcell lymphoma Transformed follicular lymphoma Mantle cell lymphoma Primary mediastinal Bcell lymphoma Any 1 follow histological subtypes phase II : Diffuse large Bcell lymphoma Transformed follicular lymphoma Primary mediastinal Bcell lymphoma Measurable disease At least 1 bidimensionally measurable lesion ≥ 10 mm long diameter CT scan , MRI , xray , clinical exam Relapsed disease 1 , 1 , prior anthracyclinebased chemotherapy regimen No known brain metastasis Performance status ECOG 02 Performance status Karnofsky 60100 % More 3 month Absolute neutrophil count ≥ 1,000/mm^3* Platelet count ≥ 100,000/mm^3* Bilirubin normal** AST ALT ≤ 2.5 time upper limit normal PT PTT normal Creatinine normal Creatinine clearance ≥ 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction attribute compound similar chemical biological composition oblimersen study drug No currently active second malignancy except nonmelanoma skin cancer carcinoma situ cervix Must complete prior therapy second malignancy consider &lt; 30 % risk relapse No ongoing active infection No psychiatric illness social situation would preclude study compliance No concurrent uncontrolled illness Prior rituximab allow No concurrent immunotherapy See Disease Characteristics At least 4 week since prior cytotoxic chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy No concurrent hormonal therapy At least 4 week since prior radiotherapy recover No concurrent therapeutic radiotherapy At least 4 week since prior surgery No prior oblimersen antisense oligonucleotide therapy No concurrent anticancer agent therapies No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>